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Oxidative stress arises when there is a marked imbalance between the production and removal of reactive oxygen species (ROS)
in favor of the prooxidant balance, leading to potential oxidative damage. ROSs were considered traditionally to be only a toxic
byproduct of aerobic metabolism. However, recently, it has become apparent that ROS might control many diﬀerent physiological
processes such as induction of stress response, pathogen defense, and systemic signaling. Thus, the imbalance of the increased
antioxidant potential, the so-called antioxidative stress, should be as dangerous as well. Here, we synthesize increasing evidence
on “antioxidative stress-induced” beneﬁcial versus harmful roles on health, disease, and aging processes. Oxidative stress is not
necessarily an un-wanted situation, since its consequences may be beneﬁcial for many physiological reactions in cells. On the
other hand, there are potentially harmful eﬀects of “antioxidative stress,” especially in the cases of overconsumption of synthetic
antioxidants. Antioxidants can neutralize ROS and decrease oxidative stress; however, this is not always beneﬁcial in regard to
disease formation or progression (of, e.g., cancer) or for delaying aging.
1.Introduction
The process of aging or senescence is complex; it may derive
from a variety of diﬀerent mechanisms and is caused by a
variety of diﬀerent factors. In recent years, oxidative stress
has been implicated in a wide variety of degenerative pro-
cesses, diseases, and syndromes, including the mutagenesis,
cell transformation, and cancer; atherosclerosis/arterioscle-
rosis, heart attacks, strokes, and ischemia/reperfusion injury;
chronic inﬂammatory diseases, such as rheumatoid arthritis,
lupus erythematosus, and psoriatic arthritis; acute inﬂam-
matory problems, such as wound healing; photooxidative
stresses to the eye, such as cataract; central nervous system
disorders, such as certain forms of familial amyotrophic lat-
eral sclerosis, certain glutathione peroxidase-linked adoles-
cent seizures, Parkinson’s disease and Alzheimer’s dementia;
a wide variety of age-related disorders, perhaps even includ-
ing factors underlying the aging process itself [1]. There are
many theories trying to explain the aging process, each from
ad i ﬀerent angle. The most recent studies support the idea
that oxidative stress is a signiﬁcant marker of senescence;
this was established in diﬀerent species [2]. Harman ﬁrst
proposed the free radical theory of aging in the 1950s and
extended this idea to implicate mitochondrial production of
reactive oxygen species in the 1970s [3]. According to the
free radical theory of aging [4–7], enhanced and unopposed
metabolism-driven oxidative stress plays a major role in
diverse chronic age-related disorders. The free-radical theory
ofagingstatesthatorganismsagebecausetheircellsaccumu-
late free radical damage over time. Halliwell and Gutteridge
later suggested to rename this free radical theory of aging
as the “oxidative damage theory of aging” [8], since aging
and diseases are caused not only by free radicals but also
by other reactive oxygen and nitrogen species. Theory links
oxygen consumption, metabolism, ATP, and ROS formation
and holds that increases in ROS accompany aging and
lead to functional alterations, pathological conditions, and
even death [9]. Furthermore, impairment of mitochondrial
activity is assumed to be one of the main causes of the
aging process [10–12]. Mitochondria are the main site of
intracellular oxygen consumption and the main source of
ROS formation [10, 13, 14]. Mitochondrial ROSs originate2 Oxidative Medicine and Cellular Longevity
from the electron transport chain and the nitric oxide syn-
thase reactions. Nonmitochondrial sources of ROS include
environmental pollutants, pollutants in food, radiation,
or they are the by-products of other metabolic processes
within organisms. Majority of free radicals are generated
inside the cell rather than coming from the environment
[10, 15, 16]. The mitochondrial damage theory has been
recently reviewed by Wilken [17]. Age-related functional
deﬁcits have been observed in some, but not all, studies of
aging mitochondria, adding support to the mitochondrial
damagetheory.Theage-relatedincreasesinthelevelsofboth
oxidative damage and mutational load of mtDNA predicted
by the mitochondrial theory of aging have been conﬁrmed in
multiple species and organ systems [18]. However, whether
this damage aﬀects mitochondrial function or signiﬁcantly
modulates, the physiology of aging has remained controver-
sial [19, 20]. On the other hand, the “vicious cycle” theory,
which states that free radical damage to mitochondrial DNA
leads to mitochondria that produce more superoxide, has
been questioned by some scientists since the most damaged
mitochondria are degraded by autophagy (mitophagy),
whereas some defective mitochondria (which produce less
A T Pa sw e l la sl e s ss u p e r o x i d e )r e m a i nt or e p r o d u c et h e m -
selves [21]. Several lines of direct and indirect evidence
generated over the past two decades have demonstrated a
positive relationship between the increased oxidative stress
in vivo and biological aging. In reality, the oxidative damage
potential is greater than antioxidant defense, and thus there
is a constant free radicals formation in low amounts, which
escapes the cell defenses. Estimates of how much oxygen
is turned into free radicals vary; however, typically cited
values are around 1.5–5% of the total consumed oxygen
[7, 22]. These estimates have been questioned by Hansford
et al. [23] and Staniek and Nohl [24], who suggested that
H2O2 production rates were lower than 1% of consumed O2.
Yet, even if we accept a conservative value of 0.15%, it still
represents a substantial amount of free radicals formation
[25]. Thus, high levels of reactive oxygen species (ROS)
compared to antioxidant defenses are considered to play a
major role in diverse chronic age-related diseases and aging.
Reduction of oxidative stress was reported to be associated
with prolongation of life expectancy, and ROS-lowering
interventions were proposed as antiaging strategies [26–40].
Since a biological antioxidant has been deﬁned as any
substance that, when present at low concentrations com-
pared to those of an oxidizable substrate, signiﬁcantly delays
orpreventsoxidationofthatsubstrate[8],thequestionsarise
whether reduction of oxidative stress in cell environment
withantioxidanttreatmentwouldbebeneﬁcial;howitwould
inﬂuence the health outcome and what adverse eﬀects could
this trigger. At this point, it should be stressed that the
antioxidants cannot distinguish among the radicals that play




leading to potential damage.” The term “antioxidative stress”
was used for the ﬁrst time by Dundar and Aslan [41] for the
negative eﬀects of antioxidants. Here, we present and discuss
the evidence on how “antioxidative” and oxidative stresses or
antioxidative imbalance can be damaging for the organism
on the examples of cancerogenesis and aging process.
2.AntioxidantsandHumanTrials
The results of many clinical trials in which individuals
received one or more synthetic antioxidants failed to obtain
beneﬁcial results. Recent evidence suggests that antioxidant
supplements(althoughhighlyrecommendedbythepharma-
ceuticalindustryandtakenbymanyindividuals)donotoﬀer
suﬃcient protection against oxidative stress, oxidative dam-
age or increase the lifespan. Some recent studies showed that
antioxidant therapy has no eﬀect and can even increase mor-
tality [42–53]. Schulz and coworkers showed that nutritive
antioxidants completely abolish the extension of lifespan by
inhibiting an adoptive reaction to ROS called mitohormesis
[54]. It was demonstrated by in vivo and in vitro studies that
vitamin C, vitamin E, SOD, glutathione and beta carotene
have a potential to cause also “antioxidative stress” in ad-
dition to prooxidative stress under certain conditions [55–
59]. There are evidently homeostatic mechanisms in cells
that govern the amount of allowable antioxidant activity.
This indicates that other substances in fruits and vegetables,
or a complex mix of substances (e.g., inhibitors of P450
from grapefruit, garlic; inhibitors of cell proliferation, e.g.,
resveratrol, green tea polyphenols, curcumin; antagonists of
estrogen, e.g., some ﬂavonoids; inhibitors of metastases, like
some ﬂavonoids; inhibitors of angiogenesis, like genistein,
epigallocatechin gallate), contribute to better cardiovascular
health and decreased cancer incidence observed in individu-
a l sw h oc o n s u m em o r eo ff r u i ta n dv e g e t a b l e[ 60, 61].
Dosing the cells with exogenous antioxidants might
decrease the rate of synthesis or uptake of endogenous
antioxidants, so that the total “cell antioxidant potential”
remains unaltered. Cutler described “the oxidative stress
compensation model” which explains why dietary supple-
ments of antioxidants have minimum eﬀect on longevity
[62, 63]. Most humans are able to maintain their set point
of oxidative stress and so no matter how much additional
antioxidant supplement they consumed in their diet further
decrease in oxidative stress does not occur. Antioxidant sup-
plements thus do not appear to signiﬁcantly decrease oxida-
tive stress or/and increase life expectancy in humans [64].
Besides, to exert beneﬁcial physiological eﬀects, antioxidants
should be well absorbed in the body and reach the site of
ROS formation in cells, where they should be present and in
appropriate amounts for a suﬃcient time.
3.ROS as SignalingMolecules, Regulatorsof
TranscriptionFactor Activities,andOther
Determinantsof GeneExpression
Human cells also generate some hydrogen peroxide and
other ROS molecules deliberately to use them as chemical
s i g n a l st or e g u l a t ee v e r y t h i n gf r o mg l u c o s em e t a b o l i s mt o
cellular growth and proliferation [65]. The most commonly
synthesized ROSs are superoxide radical and NO, whichOxidative Medicine and Cellular Longevity 3
are produced by NADPH oxidases and NO synthases,
respectively, in diﬀerent places of the organism [66]. These
enzymes are highly active in most of the reproductive tissues,
indicating that some ROSs are required for reproduction.
ROSs induce various biological processes that include a
transient elevationofintracellularCa2+ concentration,phos-
phorylation of speciﬁc proteins, activation of speciﬁc tran-
scription factors, modulation of eicosanoid metabolism, and
stimulation of cell growth [67]. Nitric oxide was identiﬁed
as a signaling molecule as early as 1987 [68] and is now
a well-known regulator of some transcription factor activ-
ities and other determinants of gene expression. Hydrogen
peroxide and superoxide have similar intracellular eﬀects
[69]. ROS can aﬀect directly conformation and/or activities
of all sulfhydryl-containing molecules, such as proteins
or glutathione (GSH), by oxidation of their thiol moiety.
Among many other enzymes and membrane receptors, this
type of redox regulation aﬀects many proteins important
in signal transduction and carcinogenesis, such as protein
kinaseC,Ca2+-ATPase,collagenase,andtyrosinekinase[70].
For several transcription factors, ROSs are physiological
mediators of transcription control [71]. The well-known
examples of redox-sensitive transcription factors are nuclear
factor-κB( N F - κB) and activator Protein-1 (AP-1). Thus,
increased oxidative stress is not beneﬁcial for the cell;
however, an increase in cellular antioxidants might impact
redox regulation and signal transduction. The complete
elimination of free radicals would thus disrupt, rather than
extend, the normal functioning of the body.
In addition to ROS, regulators of transcription factor
activities and other determinants of gene expression also act
as signaling molecules. Even the products oxidized by ROS
(e.g.,lipids,proteins,sugars,andnucleicacids)mayactinthe
similar way. For example, lipid peroxidation products may
modulate signal transduction pathways and mediate bio-
logical processes through receptors or receptor-independent
pathways. At the same time, it has been shown that the
lipid peroxidation products induce adaptive response and
increase tolerance against forthcoming oxidative stress by
upregulating defense capacity [72].
4. “AntioxidativeStress” andCancer
Increasing cellular viability by antioxidants prior or after
the toxic compound-induced toxicity (e.g., Cr(VI), UV-
radiation, ionizing radiation) might not always be beneﬁcial.
Carcinogen-induced growth arrest and apoptosis are at the
molecular decision point between carcinogen toxicity and
carcinogen carcinogenesis [73]. When normally growing
cells are in contact with carcinogens, they may respond
by undergoing growth arrest, apoptosis, or necrosis. A
population of genetically modiﬁed cells may also emerge,
which exhibits either intrinsic or induced resistance to
apoptosis[73].ControlofintracellularconcentrationofROS
is critical for the survival of cancer cells. It was demonstrated
recently in human lung cancer cells that acute increases in
intracellular concentrations of ROS caused the inhibition
of glycolysis through glycolytic enzyme pyruvate kinase M2
thus diverted the glucose ﬂux into the pentose phosphate
pathway [74]. This generated suﬃcient reducing potential
(antioxidant response) for detoxiﬁcation of ROS. This
promoted the metabolic changes required for proliferation
and enabled the cancer cells to withstand oxidative stress.
Therefore, precancer cells may lead to neoplasia as a result of
their altered growth/death ratio, due to disrupted cell cycle
control, genomic instability, or altered metabolism. This,
however, raises the question whether decreasing carcinogen
toxicity by antioxidants might actually increase the incidence
of cancer by allowing the inappropriate survival of altered
cells. This hypothesis was conﬁrmed by human intervention
studies in which smoking male volunteers were exposed
for 5–8 years to daily supplements of vitamin E and beta
carotene. The overall mortality of male smokers increased
in those taking supplements of beta carotene and was most
probably due to its eﬀect on cell proliferation [8, 75].
Supplementation by alpha-tocopherol or beta-carotene did
not prevent lung cancer in older men who smoke [75].
Beta-carotene supplementation at pharmacologic levels may
modestlyincreaselungcancerincidenceincigarettesmokers,
and this eﬀect may be associated with heavier smoking
and higher alcohol intake. Randomized human trials have
demonstrated the antineoplastic and neoplastic eﬀects of
antioxidants, with neoplastic eﬀects in patients from higher
risk groups due to smoking and alcohol consumption,
or patients undergoing chemo- or radiation therapy. The
inﬂuence of “antioxidative” stress and cancer was conﬁrmed
alsobythestudyofSchaferandcoworkers[76],whorevealed
an unanticipated mechanism for survival of epithelial cells
detached from the extracellular matrix. Normally such cells
lose the ability to take up glucose, which results in ATP
deﬁciency. Such cells do not survive normally in these condi-
tionsbutcanberescuedthroughtwodiﬀerentpathways.The
expressionofcancer-promotingoncogeneErbB2indetached
endothelial cells restores the cell’s ability to take up glucose
and reduces the levels of ROS through the antioxidant-
generating pentose phosphate pathway. Alternatively, the
ATP deﬁciency could be rescued by antioxidant treatment,
which stimulates fatty acid oxidation otherwise inhibited
by detachment-induced ROS. The latter cell rescue occurs
without the rescue of glucose uptake. Therefore, the addition
of antioxidants promotes the survival of preinitiated tumor
cells even in unnatural matrix environments by altering
metabolic regulation, which results in enhanced malignancy
[76].
Antioxidants may thus have dichotomous activities with
respect to tumorigenesis, namely, suppressing tumorigenesis
by preventing oxidative damage to DNA [77, 78]a n d
promoting tumorigenesis by allowing survival of cells that
are metabolically impaired (e.g., in altered matrix environ-
ments).
Also, iron metabolism, iron balance, and iron stores in
relations with antioxidants (Fenton’s chemistry) are impor-
tantinROS-induceddamage(seeSection4.1).Giventhatthe
cells require iron, restricting its supply could also limit the
growth of cells, including tumor cells [79–90]. Conversely,
the iron carrier neutrophil gelatinase-associated lipocalin
(NGAL, Siderocalin) is overexpressed in tumours [91–93].4 Oxidative Medicine and Cellular Longevity
The role of iron-promoting oncogenesis is documented well
[94–110].
4.1. Is Iron Overload the Reason Why Human Trials with Syn-
thetic Antioxidative Supplements Failed to Obtain Beneﬁcial
Results? Potential strategies to decrease oxidative stress may
involve not only overall reduction of oxidative stress but
also the use of iron and other metal chelators hampering
Fenton-type chemistry [111]. Harmful reactions, in which
partially reduced oxygen species such as superoxide (O2
•−)
a n dh y d r o g e np e r o x i d e( H 2O2)m a yb ef o r m e d ,a r e ,i np a r t ,
mediated by redox-active metals, the most physiologically
relevant of which are iron and copper. These transition metal
ions can play an important role in ROS production in the
cell. Reduced forms of redox active metal ions participate
in the Fenton reaction where the hydroxyl radical (HO
•)i s
generated from hydrogen peroxide.
Fenton Reaction
Metal





Fe2+ +H 2O2 −→ Fe3+ +O H
• +OH
− (2)
Furthermore, the Haber-Weiss reaction, which involves
the oxidized forms of redox active metal ions and superoxide
anion, generates the reduced form of metal ion, which can
be coupled to Fenton chemistry to generate hydroxyl radical
(see also below). Superoxide and H2O2 themselves are not
excessively reactive; thus, they are not especially damaging at
physiological concentrations. However, their reactions with
poorly liganded iron species can lead to the production of
hydroxyl radical, which is extremely damaging, and a major





(n+1) +O 2 (3)
For example,
Fe3+ +O 2





In the net reaction molecule of hydrogen peroxide is
converted into hydroxyl radical and water in the presence of
ironasacatalyst.Becausetheironconcentrationinbiological
systems is often very low, the very important factor for
Fenton chemistry activity in biological systems is the pres-
ence of functional metal redox-cycling mechanism [113].
Superoxideanionradical(O2
•−)orcertainantioxidants(e.g.,
ascorbate) play the role of such reducing agent in biological
systems. Antioxidants reduce Fe(III) to Fe(II) which reenters
the Fenton reaction. Thus, although ascorbate (or some
other antioxidant) is “reducing” and an “antioxidant” agent,
its reaction with O2, especially when catalyzed by Fe(II),
produces superoxide and thence HO• radicals that have
prooxidant properties. It is clear that any increase in the
levels of superoxide anion, hydrogen peroxide or the redox
active metal ions are likely to lead to the formation of high
levels of hydroxyl radical by the chemical mechanisms listed
above.
Some compounds contribute to antioxidant defense
by chelating transition metals and preventing them from
catalyzing the production of free radicals in the cell. Metal-
chelating antioxidants such as transferrin, albumin, and
ceruloplasmin avoid radical production by inhibiting the
Fenton reaction catalyzed by copper and iron. Particularly
important is the ability to sequester iron, which is the func-
tion of iron-binding proteins such as transferrin and ferritin
[114]. The cellular pools of low-molecular-weight iron are
not characterized well [115, 116]. If these are in contact with
ascorbate (or other antioxidants), prooxidant eﬀects may
occur. As already mentioned, ascorbic acid reduces Fe(III)
to Fe(II) which reduces oxygen to hydroxyl radical [117].
According to Herbert [118], every advertisement and label
for iron supplements and/or vitamin C should warn the
consumers: “Do not take this product until your blood iron
status has been determined.” Six percent of Americans have
the negative iron balance, and such multivitamin/mineral
product may help them. Twelve percent of Americans have
positive iron balance, and such product may hurt them.
If the inappropriate iron balance is a confounding factor
in trials with antioxidants, then the ranges of negative
eﬀects from these studies should overlap with those of iron
balance. Indeed, there was approximately 5–15% rise when
diﬀerent antioxidants were assessed for increased mortality.
For example, when the diﬀerent antioxidants were assessed
separately in the study of Bjelakovic et al. [49], there was
a signiﬁcantly increased mortality by vitamin A (RR 1.16,
95% CI 1.10 to 1.24), beta-carotene (RR 1.07, 95% CI 1.02 to
1.11),andvitaminE(RR1.04,95%CI1.01to1.07);however,
there was no signiﬁcant detrimental eﬀect of vitamin C (RR
1.06, 95% CI 0.94 to 1.20). The eﬀects of a combination of
beta carotene and of retinol (vitamin A) on the incidence
of lung cancer were compared by Omenn et al. [42]. The
relative risk of death from any cause was 1.17 (95 percent
conﬁdence interval, 1.03 to 1.33) in the treated group: 1.46
(95 percent conﬁdence interval, 1.07 to 2.00) of death from
lung cancer and 1.26 (95 percent conﬁdence interval, 0.99
to 1.61) of death from cardiovascular diseases. As there is
no direct evidence to connect the inappropriate iron balance
with antioxidants treatment, the only conclusion could be
that iron status should be considered in further clinical trials
with antioxidants.
Dietary antioxidants can therefore act in complex and
synergistic ways depending on iron status and promote the
production of OH
• radicals in the presence of inappro-
priately or inadequately liganded Fe(II) [119–122]. In this
regard, the use of elemental iron plus ascorbate in food
supplements [123] does not seem appropriate. The problem
of iron overload increases with aging since iron stores tend
to increase with age [124–128], partly due to dietary reasons
[129–131]. Several commonly used dietary vitamin andOxidative Medicine and Cellular Longevity 5
mineral supplements may be associated with increased total
mortality risk in elderly women; this association is strongest
when supplemented iron [47]. On the other hand, anemia
was reported in older population [132, 133]. Killilea et al.
[134] reported additionally that the iron content of cells
increases also as the cells age normally. Some excessive iron
canberemovedfromthebodybyregularbloodtransfusions,
like in the case of haemochromatosis. Additionally, certain
polyphenols inhibit the absorption of iron. Flavonoids act
as antioxidants, through, both, free radical scavenging and
metal chelation [135]. Many other iron chelators have been
reviewed elsewhere (e.g., [85, 86, 112]). The reduction of
redox stress thus requires appropriate amounts of both
antioxidants and eﬀective iron chelators.
Additionally, calorie restriction (CR) is thought to be the
only experimental manipulation that considerably increases
both mean and maximum lifespan in a phylogenetically
wide variety of animals [136]. CR provokes a mild stress
response, causing enhanced cell defences and metabolic
changes, coordinated by the endocrine system. CR may
improve iron status, since age-related iron accumulation was
found to be markedly suppressed by dietary restriction (DR)
in all tissues of 344 male Fischer rats [137]. This improved
iron status could in part promote longevity [138]. While
we have comparatively little inﬂuence on the production of
superoxide and peroxide in mitochondria, we can try and
improve the speciation of iron ions by pharmacological or
dietary means [112].
5. ROS and AdaptiveResponses
The key to the future success of regulating oxidative stress
induced damage should be the suppression of oxidative
damage without disruption of the well-integrated antioxi-
dant defense network. Approach to neutralize free radicals
with antioxidants should be changed into prevention of
free radical formation in the ﬁrst place. Evidence that such
approaches are possible was summarized in the recent article
by Poljsak [2].
The term “hormesis” describes beneﬁcial actions result-
ing from the response of an organism to a low-intensity
stressor. The basic concept behind the idea of hormesis is
to provoke the intrinsic capability of a body rather than to
supply exogenous natural or synthetic antioxidants to try to
compensate for age-related decline of physiological activities
in the overall maintenance mechanisms of life [139].
Hormetic pathways activated by phytochemicals may
involve kinases and transcription factors that induce the
expressionofgenesthatencodeantioxidantenzymes,protein
chaperones, phase-2 enzymes, neurotrophic factors, and
other cytoprotective proteins. Speciﬁc examples of such
pathways include the sirtuin/FOXO pathways, the NF-κB
pathway, and the Nrf-2/ARE pathway [140]. Examples
of moderate (usually intermittent) stress inducers include
ischemic preconditioning, exercise, and dietary energy
restriction [141]. The work of Lee and Yu [142], Koizumi
et al. [143], and Chen and Lowry [144]s t r o n g l ys u g g e s t
that food restriction (energetic stress) enhances the overall
antioxidant capacity to maintain the optimal status of intra-
cellular environments through the concerted interactions of
cellularcomponentstoregulateROSandmembranestability
against peroxidative stress [137]. However, recent studies
do not provide compelling evidence that the CR-associated
longevityismediatedbyantioxidants[145].Attentionisthus
directed to other targets of nutrient signaling that result in
the increased production of cytoprotective and restorative
proteins in cells.
Finkel and Holbrook [146] stated that the best strategy
to enhance endogenous antioxidant levels may actually be
oxidative stress itself, based on the classical physiological
concept of hormesis. Studies have reported the antiaging and
life-prolonging eﬀects of a wide variety of the so-called stres-
sors, such as prooxidants, aldehydes, H2O2 [147], CR [148–
151], shear stress [152, 153], irradiation [154], radiation
stress[155],UV-radiation[156],physicalexercise[157],heat
shock, hyperbaric conditions [158], and hypergravity. ROS
production is increased by several environmental factors of
stress, such as exposition to high levels of light, drought,
heavy metals, salt concentrations, temperature extremes, air
pollution, UV radiation, herbicides, and pathogen attacks.
Whether ROS will act as damaging, protective, or signaling
factors depends on the delicate equilibrium between ROS
production and scavenging at the proper site and time
[159]. Heat and cold can also work as hormesis agents
[160–164]. Thermal stress induces a heat-shock response
involvingincreasedexpressionofheat-shockproteins(HSP).
Overexpression of certain HSPs in the mitochondria can
signiﬁcantly extend the longevity of normal-lived animals
[165, 166]. The so-called adaptive response processes may
explain how ROS formation could culminate in promotion
of health and life span. For example, moderate physical
activity enhanced mitochondrial activity and subsequently
increased ROSs formation that ultimately induces an adap-
tive response, which culminates in metabolic health and
extended longevity. On the other hand, health-promoting
eﬀects were demonstrated to be reduced, if the subjects
exposed to physical activity were treated also with antioxi-
dant supplements [167, 168].
AccordingtoRistowandSchmeisser[145],endogenously
produced ROS presumably not only induce ROSs defense
enzymes, but also increase activities of phase II response
enzymes that protect from damage beyond ROS. Increased
oxidative stress over extended period of time is harmful
as well as is the extended period of antioxidative stress.
Increased ROSs induce endogenous defence mechanisms
culminating in increased stress resistance. Interestingly, low
doses of ROS with intermittent duration seem to exert the
hormesis eﬀects, whereas higher doses of ROS are unques-
tionably detrimental [145]. The question arises weather Le
Chatelier’s principle can be used also in situation of antiox-
idative stress to predict the eﬀect of a change in conditions
on a chemical equilibrium. The principle states
“If a system in equilibrium is subjected to a stress
the equilibrium will shift in the direction which
tends to relieve that stress.”6 Oxidative Medicine and Cellular Longevity
6. The Importance of Determination of the
Oxidative/AntioxidativeStatusIn Vivo
To establish the mechanism of toxicity as ROS mediated,
there are direct and indirect methods. Direct methods relate
to ROS measurement such as superoxide, H2O2,O H
•. These
species are very reactive, and their quantitation can be
diﬃcult. The only technique that can detect free radicals
directly is the spectroscopic technique of electron spin
resonance (ESR), sometimes called electron paramagnetic
resonance (EPR). The indirect methods are used in order
to overcome these problems. Indirect methods usually
measure changes in endogenous antioxidant defense systems
or measure the products of damage by ROS among the
cellular components [169]. Therefore, changes in endoge-
nous antioxidant defense systems and damages on cellular
components, caused by ROS, are measured by indirect
methods. The principle behind ﬁngerprinting methods is to
measure products of damage by ROS, that is, to measure
not the species themselves but the damage that they cause.
Measuring the damage caused by ROS instead of direct
measuring of ROS seems logical, since it is the damage
causedbyROSthatisimportantratherthanthetotalamount
of ROS generated. A good marker of oxidative damage
must be increased in the presence of oxidative stress, and
it must remain unchanged in its absence [170]. The marker
must measure a product that is endogenously present, not
produced during the isolation procedure. Multiple methods
of measurement are available today, each has their own
beneﬁts and limitations. Ascertaining the true importance of
ROS has been hard, as these evanescent species are diﬃcult
to measure in vivo. It is generally accepted that two or more
assays should be used whenever possible to enhance their
validity, since diﬀerent parameters are measured by diﬀerent
assays. There are inherent limitations in all methods, and
no method can be said to measure accurately the amounts
of ROS by itself [171]. For example, in order to determine
oxidative stress, both, the ROS potential as well as the
antioxidative defense potential should be measured. Besides,
it is not possible for a reactive free radical produced in
an extravascular space of living tissue, with a lifetime of
microseconds, to diﬀuse into the blood to be detected at
the distant site. Numerous in vitro methods are described
for the antioxidation potential determination that are easy
to perform and largely used in screening. However, the
results of such tests are relevant only partially for humans
as certain active compounds (e.g., those with large molecular
masses) are poorly absorbed from the gastrointestinal tract
and/or may undergo metabolic degradation. Therefore, new
experimental models are required to provide information
if protective eﬀects take place in humans under realistic
conditions.
There are many challenges regarding the methodology
for oxidative state detection on cellular level, for example,
which method(s) to use, which antioxidant should be used
for a standard, on the most appropriate positive control
(e.g., an oxidising agent or catalysts of Fenton reaction),
and so forth. There are no speciﬁc recommendations on
methodswhichevaluatebesttheoxidativestressinbiological
systems although there are several test systems with diﬀerent
end-points [169]. Additionally, there are no reference values
of what is the optimal antioxidative potential in urine,
blood, or even intracellularly. It is not known how much
antioxidants and in which combinations they are needed
for a beneﬁcial antioxidant eﬀect in vivo. Besides, typical
oxidative stress status of an individual is not established
yet because it is diﬃcult to measure [172]. Determination
of antioxidative potential per se is thus not enough, since
it is diﬃcult to establish how the individual antioxidants
work:bypreventingtheformationofROS,byscavengingfree
radicals, by inducing the signaling pathways, or by repairing
theoxidativedamage.Theimprovementinmethodologywill
likely overcome at least some of these drawbacks.
7. AntioxidantSupplements andthe
Consequences of OxidativeImbalance
Mitochondria are the main site of intracellular oxygen con-
sumption and the main source of ROS formation [10–14].
CellularandtissuedefensesagainstROSincludetheenzymes
superoxide dismutase (Mn-SOD, Cu/Zn-SOD, extracellular
(EC)-SOD), catalase, glutathione peroxidase, peroxiredox-
ins, and the nonenzymatic antioxidants, like glutathione
(GSH), thioredoxin, ascorbate, α-tocopherol, and uric acid
[173]. In reality, the oxidative damage potential is grater
than antioxidant defence, and thus there is a constant
small amount of toxic free radical formation, which escapes
the cellular defenses. These may lead to a conclusion that
endogenous levels of antioxidants are not high enough to
ﬁght the stress insults and that the addition of exogenous
antioxidants could enhance the cellular antioxidant capacity.
On the other hand, low levels of ROS function as sig-
nalling molecules to induce adaptive responses. Over-
consumption of exogenous antioxidants could thus lead to
the state of “antioxidative” stress, where antioxidants might
attenuate or block the adaptive stress responses. Addition-
ally, reactive oxygen species in moderate concentrations
are essential mediators of defence against microorganisms
and unwanted cells. Thus, if administration of antioxidant
supplements decreases the levels of free radicals, this may
interfere with essential defence mechanisms for removal of
damaged cells, including those that are precancerous and
cancerous [174]. Therefore, antioxidant supplements may
actually cause some harm [44, 175–177]. Our diets typically
containsafelevelsofvitamins;however,supplementingthem
with high levels of antioxidant supplements can potentially
upset an important physiological balance [44, 175–177].
A systematic review and meta-analysis done by Bjelakovic
et al. [176] concluded that the long-term treatment with
beta carotene, vitamin A, and vitamin E may increase
mortality. It is not known whether the increased mortality
is due to iron overload, adaptive stress response prevention,
repression of immune system, or any other mechanism. Pre-
sented ﬁndings provide indirect evidences for the hypothesis
that “anti-oxidative” stress inﬂuences ROS production and
subsequently inappropriate induction of ROS defenses. On
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Figure 1: Early detection of “antioxidative” or oxidative stress
enablessuccessfulpreventionandtreatment.Thewindowofoppor-
tunity for detection and modulation of oxidative imbalance should
be explored in order to timely recognise and ameliorate the oxida-
tive imbalance to prevent or postpone its consequences, namely, the
free radical-related disease development and premature aging.
period of time increases oxidative damage with negative
inﬂuences on health and longevity.
Oxidative or “antioxidative” stresses occur early in the
process that may lead to pathology; therefore, they are not
associated with any speciﬁc clinical symptoms or signs at an
early stage. Often they are not recognized until the develop-
ment of irreversible damage to the patient that manifest itself
as a symptom of a chronic disease. It is therefore important
to recognise oxidative imbalance at an early stage in order
to prevent the long-term oxidative and antioxidative stresses
(Figure 1). These point to the need for determination of
individual’s oxidative status before starting or ending the
supplement therapy with antioxidants. This may prevent or
reverse the development of diseases which arise because of
chronic oxidative imbalance.
The question arises weather determination of individ-
ual’s oxidative balance/imbalance status would lead to a
better preventive or therapeutic interventions that may slow
down the aging process. If so, who would beneﬁt from
it most? We believe that individuals with oxidative stress
because of their diets, lifestyle, metabolic errors, exposure to
environmentalpollutionorironoverloadwouldbeneﬁtfrom
regular monitoring of their oxidative status. The individuals
who overdose antioxidant supplements and enter the status
of “antioxidative” stress may beneﬁt even more.
8. Conclusion
Thecurrentlevelofawarenessofsafetyandqualityofsupple-
ments with antioxidative properties is inadequate, as there
are still many gaps in our knowledge regarding the mech-
anisms of bioavailability, biotransformation, and action of
these supplements. There are several studies in which the
addition of antioxidants aﬀected and even increased the
mortality.
Exogenous antioxidants tend to depress the endogenous
antioxidant levels. Changing the level of one antioxidant
causes a compensatory change in the levels of others, while
the overall antioxidant capacity remains unaﬀected. Dosing
cells with exogenous antioxidants might decrease the rate of
synthesis or uptake of endogenous antioxidants, so that the
total “cell antioxidant potential” remains unaltered. Thus,
the key to future success of dietary antioxidant supplemen-
tation should be in the suppression of oxidative damage
without the disruption of the well-integrated antioxidant
defense network.
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